Unveiling the Therapeutic Landscape of Oseltamivir: Exploring Drug Utilization, Adverse Reactions and Interactions with Comorbidities-A Prospective Study

Journal Title: Open Access Journal of Pharmaceutical Research - Year 2024, Vol 8, Issue 1

Abstract

Objective: This study aimed to investigate adverse drug reactions (ADRs) associated with Oseltamivir in the presence of various co-morbidities. The objective was to analyze prescription patterns, administration rationale, and ADR prevalence among patients receiving Oseltamivir for therapeutic or preventative purposes. Material and Methods: The study, conducted over six months at St. Philomena’s Hospital in Bengaluru, involved patients of all ages and genders. Ethical approval secured, the research gathered data from diverse sources for 140 patients. Naranjo’s scale was employed for causation, severity, and preventability assessments of Oseltamivir-related ADRs. Descriptive statistics were utilized to compare ADR frequencies between patients using Oseltamivir for prevention and those for therapeutic purposes. Results: The study revealed a 3.57% incidence of Oseltamivir-related ADRs, with co-morbidities contributing to 2.8% of cases, predominantly associated with hypertension. The research shed light on the importance of monitoring ADRs, particularly in the context of co-morbidities during Oseltamivir treatment. Conclusion: This research underscores the importance of monitoring ADRs in the context of co-morbidities during Oseltamivir treatment. The prevalence of hypertension as the most common co-morbidity highlights the need for careful prescription practices, especially for individuals with underlying medical conditions. These findings provide valuable insights into optimizing Oseltamivir usage in diverse patient populations.

Authors and Affiliations

Prasad SD, Satyender K*, Rakesh KS, Amrish C, Seema and Dinesh K

Keywords

Related Articles

Study on the Prevalence of Hyperuricemia and Ethnobotanicals Associated with Gouty Arthritis in Rawalakot, Azad Kashmir

Hyperuricemia prevalence is an exclusive condition in the global populace as it seems to have increased day by day for a long time now. Recent studies recommend that hyperuricemia is an issue and is considered an indepe...

C-termini Analysis of Monoclonal Antibody Fragmentation

Fragmentation of therapeutic monoclonal antibodies (mAbs) is a critical quality attribute (CQA) that needs to be monitored and controlled during the biopharmaceutical drug development. Fragmentation of a protein is a res...

Angiotensin II Contributes to the Pathophysiology of Heart Failure

Angiotensin is a protein hormone; it is a part of the renin-angiotensin system (RAS), that causes blood vessels to become narrower, helps to maintain blood pressure and fluid balance in the body. It is the primary effect...

Irrational Use of the Treatment for H. Pylori Guidelines

The gastric ulcer is epidemic disease in many countries the main cause of the disease is helicobacter pylori which transfers by polluted foods. Many protocols and guidelines for the treatment and the most common guidelin...

Computerized Systems Validation (CSV) in Biopharmaceutical Industries

The biopharmaceutical industries has more and more used computers to support and accelrate producing of their products. Computer systems also are accustomed support routine offer of high quality products to boost produc...

Download PDF file
  • EP ID EP751872
  • DOI 10.23880/oajpr-16000301
  • Views 2
  • Downloads 0

How To Cite

Prasad SD, Satyender K*, Rakesh KS, Amrish C, Seema and Dinesh K (2024). Unveiling the Therapeutic Landscape of Oseltamivir: Exploring Drug Utilization, Adverse Reactions and Interactions with Comorbidities-A Prospective Study. Open Access Journal of Pharmaceutical Research, 8(1), -. https://europub.co.uk/articles/-A-751872